Sareum Holdings Secures US Patent for Autoimmune Therapy

Sareum Holdings (GB:SAR) has released an update.

Sareum Holdings PLC has announced the forthcoming US patent for SDC-1801, a promising treatment for autoimmune diseases, with the US Patent and Trademark Office issuing a Notice of Allowance. This patent will protect the compound’s chemical structure, uses, and synthesis methods, complementing existing approvals in Europe, China, and Japan. The company anticipates the formal grant of the US patent by the end of 2024, bolstering its intellectual property portfolio as it advances clinical development.

For further insights into GB:SAR stock, check out TipRanks’ Stock Analysis page.